Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00006174
Other study ID # 000183
Secondary ID 00-D-0183
Status Completed
Phase Phase 1
First received August 11, 2000
Last updated June 30, 2017
Start date August 3, 2000
Est. completion date May 18, 2009

Study information

Verified date May 18, 2009
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test the safety and effectiveness of letrozole in treating precocious (early) puberty in girls with McCune-Albright syndrome (MAS). The physical changes of puberty, such as breast enlargement, menstruation and growth spurt, as well as the emotional changes of this developmental stage, usually begin in girls between the ages of 8 and 14. Girls with MAS, however, often begin puberty before age 7. In MAS, large ovarian cysts produce high levels of estrogens (female hormones) that cause the changes of puberty. Children with MAS also have polyostotic fibrous dysplasia (PFD), a disease of bones that, depending on what parts of the skeleton are affected, can lead to broken bones or disfigurement of the head, face, arms and legs, or can cause pressure on nerves and blood vessels. Many children with MAS have cafe-au-lait spots (increased pigmentation) on areas of their skin as well.

Letrozole is an estrogen-lowering drug that has been approved for treating women with breast and other cancers. Although the drug has not been tested or approved for use in children, some pediatric specialists have given it to girls with precocious puberty and MAS and found that it improves their condition without harmful side effects. This study will examine whether letrozole can lower estrogen in girls with MAS and arrest puberty. It will also study the drug's effects on substances involved in bone growth, including calcium, phosphate and amino acids.

Girls 1 to 8 years old with MAS may be eligible for this study. Patients who were enrolled in NIH protocol 98-D-0145 (Screening and Natural History of Patients with Polyostotic Fibrous Dysplasia and the McCune-Albright syndrome) are also eligible. Participants will be admitted to the hospital for 2 to 3 days every 3 months for 15 months, for a total of 6 visits. They will undergo a complete history and physical examination and routine blood and urine tests every visit, as well as evaluations of their general health, growth and bone development, endocrine system (hormone-secreting glands) status and PFD status. A hand X-ray will be taken at the first visit and every 6 months to measure bone age advance. The children will begin taking letrozole at the second visit and continue the drug for 6 months. They will be evaluated after 3 months and 6 months on the drug (visits 3 and 4), and again after 3 months and 6 months after stopping treatment (visits 5 and 6).

Parents of children who weigh more than 18 kilograms (about 40 pounds) may be asked if extra blood may be drawn after 3 months (visit 3) and 6 months (visit 4) of treatment to measure letrozole levels. The blood will be drawn before the morning dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after the dose through an indwelling needle placed in the vein for 8 to 24 hours.

Parents will keep a record of all episodes of menstrual bleeding and any other symptoms or complaints. Children who respond well to therapy (decreased menses, slowed breast development, slowed growth and bone age advance) will be offered another 12 months of letrozole treatment.


Description:

Girls ages 1 - 8 years with the McCune-Albright syndrome (MAS) and girls with other conditions characterized by precocious puberty due to estrogen hypersecretion from ovarian cysts will be eligible for this pilot study. Patients who have previously enrolled in Protocol 98-D-0145 (Screening and natural history of patients with polyostotic fibrous dysplasia and the McCune-Albright Syndrome) will also be eligible. Patients will be treated with letrozole, a potent, nonsteroidal aromatase inhibitor, to suppress their elevated serum estrogen levels. We will confirm the safety and efficacy of letrozole, and study its effectiveness in controlling the elevated sex steroid levels, and the advanced rates of linear growth, bone maturation, and pubertal progression in these patients. We will also study the effect of decreased estrogen levels on the status of their polyostotic fibrous dysplasia by measuring serum and urine values for bone biomarkers, including calcium, phosphate, organic amino acids, and vitamin D metabolites, which are known to be abnormal in many patients with MAS. Patients will act as their own controls. We will compare serum and urine parameters of pubertal progression and bone biomarkers before, during, and after discontinuation of letrozole. This trial will be carried out in parallel with in-vitro and in-vivo laboratory studies using an animal model of fibrous dysplasia. In this model, osteogenic precursor cells from patient bone biopsies will be cultured in a hydroxyapatite/tricalcium phosphate matrix and transplanted into immunocompromised mice. We anticipate that our laboratory findings will complement the care of our patients, resulting in more effective treatment for the precocious puberty and the bone disease in children with MAS. Because our initial studies have indicated that letrozole is effective in treating precocious puberty in MAS patients, this protocol also enrolls girls who have a related condition, gonadotropin-independent precocious puberty without the bone disease polyostotic fibrous dysplasia. We also believe that this study complements the recent FDA and NIH mandates that children be included in the evaluation of pharmaceutical products and in federally funded clinical research studies.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date May 18, 2009
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 1 Year to 8 Years
Eligibility - INCLUSION CRITERIA

Patients will be girls age 1-8 years with precocious puberty (menses, and/or breast development, and/or BA greater than plus 2SD [for chronologic age] and/or linear growth rate greater than plus 2SD) and polyostotic fibrous dysplasia due to MAS.

All ethnic groups will be included.

EXCLUSION CRITERIA

Boys with MAS will be excluded.

Patients with clinically significant hepatic and/or renal impairment will be excluded.

Study Design


Intervention

Drug:
Letrozole


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01944488 - LH Response to GnRH Test in Prepubescent Girls Under 6 Years N/A
Not yet recruiting NCT01944475 - Follow-up of Girls With Premature Thelarche and Precocious Puberty N/A
Completed NCT00564850 - Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty Phase 3
Completed NCT00001181 - Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty Phase 2
Recruiting NCT04113070 - Overweight and Obesity and Puberty Development Cohort Study
Recruiting NCT01601171 - Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
Completed NCT00734279 - Follicle-Stimulating Hormone (FSH) and the Onset of Puberty Early Phase 1
Recruiting NCT05338411 - Effect of Exogenous Growth Hormone on Ocular Findings
Recruiting NCT06280807 - Observation of Environment and Reproductive-Endocrine Effects
Completed NCT00004344 - Purification of Testis-Stimulating Factor in Precocious Puberty N/A
Completed NCT00001202 - Treatment of Boys With Precocious Puberty Phase 2
Completed NCT04665713 - Effect of Prevalence of BMI on Efficacy of Herbal Medicines in Girls' Sexual Precocity
Completed NCT02199587 - The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test N/A
Terminated NCT04502836 - Evaluation of the Correlation Between Psychological Intervention, Including Providing Knowledge and Tools for Problems Solving, and the Anxiety Level of Female Patients Arriving to ACTH LRH Test - Pilot Study N/A
Completed NCT02650141 - Clinical Trial of Experienced Chinese Herbal Formulas on Different Types of Precocious Puberty N/A
Completed NCT00909844 - Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study Phase 3
Completed NCT00004335 - Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle N/A